secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lucid Diagnostics Inc. (LUCD)
CIK:        0001799011
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001493152-24-044974
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lucid Diagnostics Q3: EsoGuard rev $1.2M (+50% YoY), net loss $12.4M ($0.25/share), raises $21.75M via notes
--------------------------------------------------------------------------------

- EsoGuard revenue $1.2M, up 20% sequentially from Q2 2024 and 50% YoY from Q3 2023.
- GAAP net loss attributable to common stockholders $12.4M, or $(0.25) per share.
- Non-GAAP adjusted loss $10.1M, or $(0.20) per share, excluding stock-based comp and other non-cash items.
- Cash $14.5M at Sep 30, 2024; entered into $21.75M senior secured convertible notes to extend cash runway.
- Performed 2,787 commercial EsoGuard tests in Q3; October record >1,400 tests; clinical validation study accepted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799011/000149315224044974/0001493152-24-044974-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799011/000149315224044974/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-044974

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer